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http://dx.doi.org/10.1016/j.pedneo.2Background: To assess the effectiveness of vitamin A supplementation in very low birth weight
(VLBW) infants to prevent complications of prematurity.
Methods: This was a retrospective cohort study to determine the effectiveness of vitamin A in
preventing complications of prematurity in VLBW infants. Vitamin A was delivered intramuscu-
larly at a dose of 5000 IU, three times weekly during the first 28 days of life.
Results: Of the 187 eligible VLBW infants, we excluded from the analysis (due to death or
transfer to another hospital), 16 infants weighing <1000 g and 17 weighing 1000e1500 g. Sixty
VLBW infants received the vitamin supplement. We observed no differences between the
groups in the duration of oxygen therapy or in the risk of bronchopulmonary dysplasia. The risk
of sepsis was up to three times higher among the infants who were given the vitamin A supple-
ment.
Conclusion: Given the increased risk of sepsis in patients weighing >1000 g, the risk associated
with repeated intramuscular injections of vitamin A and the modest clinical results described,
we do not believe the universal administration of vitamin A to VLBW infants to be justified as
prophylaxis for bronchopulmonary dysplasia.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Vitamin A is a group of fat-soluble compounds involved in
regulating the growth of many epithelia that are necessary
for normal development of the retina and lungs.1 Brandt
et al2 first reported that preterm infants have lower levels ofatal, Servicio de Pediatrı´a, Hospit
Uberos).
an Pediatric Association. Publish
013.12.002plasma vitamin A than do term infants, and their findings
were subsequently confirmed by other authors.3 In an
experimental mouse model, plasma levels of vitamin A have
been shown to increase by the end of gestation, which would
account for the low levels of plasma vitamin A in the preterm
infant4,5 and justify vitamin A supplementation in extremelyal Clı´nico San Cecilio, Avenida del Doctor Oloriz 16, 18012 Granada,
ed by Elsevier Taiwan LLC. All rights reserved.
Table 1 Perinatal data, mean (SD), for infants given supplementary vitamin A and untreated infants.
1000 g 1000e1500 g
Vitamin A þ Vitamin A  Vitamin A þ Vitamin A 
Patients (n) 19 27 41 67
Gestational age (wk) 27.9 (1.8) 28.0 (2.0) 29.1 (1.5) 29.8 (1.9)
Birth weight (g) 854 (113) 906 (103) 1224 (154) 1261 (159)
Apgar score at 5 min 6.7 (1.5) 7.8 (1.9) 7.8 (1.7) 9 (1.2)y
Female infants, n (%) 12 (63.1) 14 (51.8) 15 (36.6) 36 (53.7)
Small for gestational age, n (%) 7 (36.8) 15 (55.6) 4 (9.7) 19 (28.3)*
Maternal age (y) 30.6 (6.7) 30.2 (6.1) 31.6 (5.8) 30.5 (5.6)
Cesarean section, n (%) 15 (78.9) 25 (92.5) 35 (85.3) 50 (74.6)
Completed courses of antenatal steroids, n (%) 13 (68.4.3) 26 (96.3) 25 (60.9) 34 (50.7)
Chorioamnionitis, n (%) 2 (10.5) 3 (11.1) 6 (14.6) 3 (4.5)
*p < 0.05, vitamin A þ versus vitamin A .
yp < 0.01, vitamin A þ versus vitamin A .
SD Z standard deviation.
Vitamin A and complications of prematurity 359low birth weight (ELBW) premature infants. However,
various studies have reported that such prophylactic sup-
plementation can provoke complications of prematurity,
such as bronchopulmonary dysplasia (BPD), intraventricular
hemorrhage (IVH) and retinopathy of prematurity (ROP).4,6
To prevent vitamin A deficiency in the preterm infant and
avoid repeated intramuscular (IM) administration, some au-
thors have proposed supplying vitamin A to pregnant women
in areas of endemic vitamin A deficiency.6,7
Vitamin A administered during the first weeks of life in
ELBW infants has been reported to produce a modest
improvement in respiratory outcomes.6,8 Tyson et al4
studied a series of 800 very low birth weight (VLBW) in-
fants and observed a significant reduction in oxygen
requirement and in BPD of prematurity after the IM provi-
sion of vitamin A in the first weeks of life.
Even with plasma levels of vitamin A>30 mg/dL and serum
retinol >20 mg/dL, children with BPD may have a functional
deficiency of vitamin A, as a result of excessive vitamin A
binding to plasma proteins. Furthermore, in infants with low
levels ofplasmaproteins, toxiceffectsmayoccuras a result of
the administration of vitamin A.9 Values of 80 mg/dL in serum
are considered normal in children and adults.10 However, the
values above which signs of toxicity may appear in VLBW in-
fants have not been established with certainty.11 Some au-
thors have reported increased plasma levels of vitamin Awith
postnatal steroid use, which might contribute to the devel-
opment of toxic effects in preterm infants treated with
vitamin A.9 Among the toxic manifestations of vitamin A are
vomiting, poor tolerance, and seizures, although such out-
comes are rare according to the published studies.4
Vitamin A is also an important factor for the development
of the retina and may have a protective role against the
development of ROP.8 However, the greatest impact of
vitamin A in the prevention of ROP concerns the possibility
that itmay reduce oxygendependence in thepreterm infant.6
Some authors, in clinical trial models and meta-
analyses, have demonstrated the efficacy of vitamin A in
the prevention of complications of prematurity, particu-
larly ROP and BPD.6,12 In this study we evaluate the effec-
tiveness of vitamin A supplementation in VLBW infants in
the prevention of complications of prematurity.2. Materials and methods
A retrospective cohort study was designed and imple-
mented in the neonatal intensive care unit (NICU) at San
Cecilio University Hospital (Granada, Spain) to determine
the effectiveness of vitamin A in preventing complications
of prematurity in VLBW infants, during the period from
January 1, 2008 to December 31, 2012. During this period,
the NICU treated 187 VLBW infants, of whom 33 could not
be analyzed due to death or transfer to another center for
surgery. Of those analyzed, 60 were given supplemental
vitamin A.
The study was approved by the Hospital Ethics Com-
mittee and informed consent was obtained from the parent
or guardian of the patients for the use of their data. The
use of vitamin A was approved by the Hospital Pharmacy
Committee as a compassionate use drug.
We included in the study all infants weighing <1500 g at
birth or with a gestational age <32 weeks. We excluded
children who died in the first 4 weeks of life or 36 weeks
corrected gestational age and patients transferred to other
hospitals. Our hospital does not have a pediatric surgery
department. Most of the transferred patients required
surgical attention for enterocolitis.
The following demographic variables were obtained
from the patients included in the study: birth weight,
gestational age, mode of delivery, presence of cho-
rioamnionitis, Apgar score at 5 minutes, and complete lung
maturation with antepartum steroids. We recorded the
elapsed days until the establishment of full enteral feeding,
days of parenteral feeding, days of oxygen therapy, days of
mechanical ventilation and continuous positive airway
pressure (CPAP), comorbidity associated with each group,
and finally, ROP and IVH.
BPD was defined according to the criteria of Jobe and
Bancalari13: oxygen requirement >21% at 28 days of age
and/or >21% positive pressure in the airway at 36 weeks
corrected gestational age.
In the diagnosis of sepsis, coincidence of more than one
clinical and analytical criteria from the following was
considered12,14: (1) clinical criteriadfever or hypothermia,
tachycardia or bradycardia, tachypnea or apnea, two
Table 2 Clinical results for infants given supplementary vitamin A and untreated infants.
1000 g 1000e1500 g
Vitamin A þ Vitamin A  Vitamin A þ Vitamin A 
Days in NICU 44.8 (14.0) 52.4 (22.4) 28.6 (11.2) 25.2 (17.8)
Oxygen therapy (d) 49.5 (37.6) 49.8 (30.9) 28.6 (22.1) 18.7 (18.0)*
Mechanical ventilation (d) 6 (7.8) 14.8 (20.9) 3.0 (4.2) 3.3 (6.1)
CPAP (d) 9.1 (7.7) 9.3 (7.4) 6.4 (5.9) 3.7 (4.5)*
Parenteral nutrition (d) 23.7 (11.1) 21.6 (12.2) 13.6 (7.7) 10.3 (10.1)
Full enteral nutrition (days to start of) 24.2 (11.3) 26.1 (17.4) 15.3 (8.1) 13.9 (10.8)
BPD, n (%)
Mild 5 (26.3) 12 (44.4) 12 (29.3) 12 (17.9)
Moderate 6 (31.6) 6 (22.2) 5 (12.2) 4 (6)
Severe 5 (7.4) 2 (26.3) e e
Total 16 (84.2) 20 (74.1) 17 (41.5) 16 (23.9)
Sepsis, n (%) 17 (89.5) 20 (74.1) 24 (58.5) 18 (26.9)y
Retinopathy of prematurity, n (%)
Degree 1 7 (17.5) 4 (6.8) 1 (5.6) 10 (38.5)*
Degree 2 0 (0) 2 (3.4) 1 (5.6) 1 (3.8)
Degree 3 0 (0) 8 (13.6) 5 (27.8) 8 (30.8)
Plus 0 (0 3 (5.1) 4 (22.2) 4 (15.4)
Intraventricular hemorrhage, n (%)
Degree 1 1 (5.3) 3 (11.1) 3 (7.3) 3 (4.5)
Degree 2 2 (10.5) 1 (3.7) 1 (2.4) 6 (9.0)
Degree 3 4 (21.1) 1 (3.7) 1 (2.4) 1 (1.5)
Degree 4 0 (0) 1 (3.7) e e
Death, n (%) 4 (17.4) 10 (27.0) 0 (0) 6 (8.2)
*p < 0.05, vitamin A þ versus vitamin A .
yp < 0.01, vitamin A þ versus vitamin A .
BPD Z bronchopulmonary dysplasia; CPAP Z continuous positive airway pressure; NICU Z neonatal intensive care unit.
360 J. Uberos et almeasurements at intervals of 30 minutes with average
blood pressure less than the 10th percentile for gestational
age, abdominal distension, vomiting, poor capillary refill,
or pallor; (2) analytical criteriadC-reactive protein and
procalcitonin above reference ranges for gestational age,
hyperglycemia, leukocytosis, leukopenia, thrombocyto-
penia, thrombocytosis, and positive blood culture.
With respect to the retinopathy examination protocol
for premature infants, the following inclusion conditions
were applied: preterm infant birth weight <1500 g or <32
weeks’ gestational age.
Following the procedure proposed by Kennedy et al,9
vitamin A was delivered IM at a dose of 5000 IU, three
times weekly during the first 28 days of life. Its use is
indicated in all VLBW infants who require a fraction of
inspired oxygen exceeding 21% on admission. During the
period of administration of vitamin A, plasma levels of
vitamin A were determined by liquid chromatography at 15
days and 28 days of life.15,16
The statistical analysis consisted of a descriptive anal-
ysis, a comparison of the means test for independent
samples, and c2 analysis for categorical variables.
3. Results
3.1. Perinatal results
From January 2008 to December 2012, 187 VLBW infants
were treated in our NICU. We excluded from the analysis(due to death or transfer to another hospital) 16 infants
weighing <1000 g and 17 infants weighing 1000e1500 g.
Perinatal data and the number of deceased patients are
shown in Tables 1 and 2. Among the ELBW infants, no
perinatal differences were observed between the infants
who received vitamin A and those who did not.
Among the infants weighing >1000 g, we observed a
significantly higher percentage of small-for-gestational-
age infants among those who did not receive vitamin
A, and among this group, the 5-minute Apgar score was
slightly higher.3.2. Need for oxygen therapy and nutrition
The ELBW infants given vitamin A supplementation received
oxygen treatment for periods similar to those for the in-
fants who did not have vitamin supplement. The need for
invasive mechanical ventilation and days of CPAP were also
similar. Among infants weighing >1000 g, slightly more days
of oxygen treatment were needed by the group given the
vitamin A supplement. With respect to the requirements of
mechanical ventilation and days of CPAP, no differences
were observed. During the first 2 weeks of life, the infants
with BPD (data pending publication) received significantly
lower energy intakes than did those without BPD. Never-
theless, we did not observe any statistically significant
differences between the groups for days of parenteral
nutrition or the time needed to achieve full enteral
nutrition.
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The rate of VLBW in our hospital is 12.8 per 1000 live births,
and the rate of BPD is 0.7 per 1000 live births, with a
prevalence of 59.4% among the ELBW infants and of 27.4%
among those weighing >1000 g. As shown in Table 2, there
were no statistically significant differences in the preva-
lence of BPD between the infants who were given vitamin A
and those who were not [odds ratio (OR): 2.2, 95% confi-
dence interval (CI): 0.97e5.27]. Serum levels of vitamin A
were 0.33 mg/mL [standard deviation (SD): 0.26] in the
patients with BPD and 0.25 mg/dL (SD: 0.14) in those with no
BPD, and there were no statistically significant differences
between the groups. We observed no clinical manifesta-
tions attributable to vitamin A toxicity in any of our
patients.3.4. ROP and vitamin A
The incidence of mild, moderate, and severe ROP in our
hospital is 1.5, 0.3, and 1.4 per 1000 live births, respec-
tively. Among those weighing <1000 g, ROP was no better
among the infants who were given vitamin A. However,
among the infants weighing >1000 g, there were fewer
cases of mild ROP among those given vitamin A (OR: 0.68,
95% CI: 0.24e1.9; Table 2).3.5. IVH
The rate of incidence of IVH, Grade I, Grade II, Grade III,
and Grade IV in our hospital is 0.6, 0.7, 0.6 and 0.2 per
1000 live births, respectively. We observed no differences
in the prevalence of IVH between the infants who were
given vitamin A and those who were not. The OR for IVH
in infants weighing <1000 g was 2.04 (95% CI: 0.55e7.5)
and for those weighing >1000 g it was 0.79 (95% CI:
0.25e2.5).3.6. Sepsis and vitamin A
There were no significant differences in death rates be-
tween the groups. However, regardless of birth weight, the
risk of sepsis was up to three times higher among infants
given vitamin A supplementation than among those who
were not (OR: 3.8, 95% CI: 1.6e8.7). Stratifying by birth
weight, there were no significant differences in the prev-
alence of infection among the ELBW infants (OR: 2.9, 95%
CI: 0.54e16.3). In those with a birth weight >1000 g, there
was a significantly higher prevalence of sepsis in the group
receiving vitamin A supplementation (OR: 3.8, 95% CI:
1.7e8.7). The microorganisms in our sample related to the
development of sepsis in neonates were Staphylococcus
aureus (5.9%), Klebsiella pneumoniae (35.3%), Enter-
obacter cloacae (5.9%), coagulase-negative Staphylococcus
(23.5%), Enterococcus faecalis (11.8%), Enterococcus fae-
cium (5.9%) and Enterobacter (11.8%).
The statistical power post hoc for a dichotomous
endpoint and two independent samples was 83%.4. Discussion
This study reviews our results following the introduction, in
April 2010, of vitamin A supplementation for VLBW infants
as prophylaxis for BPD. Despite the efficacy of vitamin A in
the prevention of BPD that has been demonstrated by some
authors in experimental models,8,17,18 our study obtained
no better results for BPD among vitamin-A-supplemented
than among untreated patients.
Some systematic reviews8 have reported that the IM
supplementation of vitamin A in VLBW infants is associated
with a trend towards reduced rates of death or oxygen use
at 1 month of age, with borderline statistical significance
(RR: 0.93, 95% CI: 0.86e1.0). We observed no differences in
the perinatal risk factors classically associated with BPD
between the infants who received vitamin A and those who
did not. Some authors19,20 have reported a decrease in the
prevalence of BPD in recent years. This decline has coin-
cided with improved ventilatory techniques with guaran-
teed volume utilization and a more rational use of oxygen
therapy,21,22 but also with increased nutritional inputs of
protein and energy, as recommended by the ESPGHAN.23 In
our sample, no differences were observed between the
groups concerning the duration of parenteral feeding or
days of life elapsed to achieve full enteral nutrition. Days of
oxygen therapy, CPAP and noninvasive ventilation did not
differ significantly between the groups.
Although several authors have shown that a 5-minute
Apgar score of <7 is associated with increased neurological
morbidity,24 in the short, medium, and long term, in our
sample the patients with a birth weight >1000 g who were
given vitamin A had a 5-minute Apgar score of >7. Although
there are statistical differences between these patients
and the group that was not given vitamin A, we believe that
this finding is of little clinical significance, because neither
of the two groups had a low 5-minute Apgar score (<7).
Shenai et al3 reported a trend toward decreased risk of
ROP in infants receiving vitamin A supplementation, find-
ings similar to those reported by Darlow et al,8 who based
their systematic review on Shenai et al.3 In our sample, we
only observed a decrease in Grade I ROP in the infants
weighing over 1000 g who received IM vitamin A supple-
mentation. In those weighing <1000 g, we observed a
decrease in ROP, but without statistical significance.
Some studies have reported increased episodes of sepsis
among patients receiving vitamin A supplementation,
although the differences are not statistically significant.4
Chabra et al24 observed an increased frequency of infec-
tion and/or sepsis among patients receiving supplementary
vitamin A. In our study, we also observed an increased risk
of sepsis linked to vitamin A supplementation. Stratifying
by birth weight, we observed a significantly higher preva-
lence of sepsis among the infants weighing >1000 g who
received supplementary vitamin A.
Furthermore, vitamin A supplementation for VLBW in-
fants is not without other risks.9 Some authors have re-
ported increased plasma levels of vitamin A with postnatal
steroid use, which might contribute to the development of
toxic effects in preterm infants treated with vitamin A.
Chabra et al24 in a retrospective study of preterm infants
supplemented with 5000 IU of vitamin A delivered IM,
362 J. Uberos et alobserved that few children receiving supplementary
vitamin A actually had a real vitamin deficiency. Londhe
et al25 noted that the alveolar hypoplasia caused by caloric
restriction in children with intrauterine growth retardation
can be reversed with replenishment and retinoic acid sup-
plementation. Consequently, our view is that supplements
should only be given to ELBW infants with serum vitamin A
levels below the lower limit of normality (20 mg/dL).9
Given the increased risk of sepsis in patients weighing
>1000 g and the potential risks involved in the repeated IM
administration of vitamin A, as well as the modest clinical
results reported, we believe that there is no justification
for the universal administration of vitamin A to newborn
infants weighing <1000 g. Determining the levels of vitamin
A in the first days of life can be helpful in deciding when
vitamin A supplementation should be given and when it
should not.
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